Acronym:
Checkmate 274
ACTRN/NCT /ethics:
NCT02632409
Scientific title:
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
Summary of trial and patient characteristics
| Cancer Type | Other | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase III | Tumour Stream | Urothelial carcinoma Bladder cancer |
| Age Range | 18 years and older | Cancer Stage | All stages |
| Sex | Both | Anticipated Start Date | 2016-02-11 |
| Molecular Target | Anticipated End Date | 2026-11-27 | |
| Cancer Type | Other |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Urothelial carcinoma Bladder cancer |
| Cancer Stage | All stages |
| Anticipated Start Date | 2016-02-11 |
| Anticipated End Date | 2026-11-27 |
Trial Summary
A phase III randomised, double-blind, multi-center study of adjuvant nivolumab vs. placebo in subjects with high risk invasive urothelial carcinoma
Lay Summary
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
Sponsor / Cooperative group
Bristal-Myers Squibb
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Lyell McEwin Hospital | Andy Phay | andy.phay@sa.gov.au | 08 8282 0833 | Dr Christopher Hocking | Recruitment on Hold |